Mangalam Drugs gearing up for Covid-19 drug

| Updated on March 24, 2020


Shares of Mangalam Drugs and Organics, engaged in the business of manufacturing of various active pharmaceutical ingredients (APIs) for anti-malaria, anti-retrovirals, including hydroxrychloroquine sulphate (HCQS) and chloroquine phosphate (CQP) APIs, may remain in focus. The company is gearing up production of HCQS and CQP APIs to meet the demand in case these are approved for treatment of patients affected by the novel coronavirus by regulatory authorities, it said in a statement.

Published on March 24, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor